These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37317870)

  • 41. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
    Edwards KR; Kamath A; Button J; Kamath V; Mendoza JP; Zhu B; Plavina T; Woodward C; Penner N
    Mult Scler Relat Disord; 2021 Jun; 51():102861. PubMed ID: 33773271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum glial fibrillary acidic protein is sensitive to acute but not chronic tissue damage in cerebral small vessel disease.
    Gattringer T; Enzinger C; Pinter D; Fandler-Höfler S; Kneihsl M; Haidegger M; Eppinger S; Demjaha R; Buchmann A; Jerkovic A; Schmidt R; Khalil M
    J Neurol; 2023 Jan; 270(1):320-327. PubMed ID: 36056929
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
    Aktas O; Hartung HP; Smith MA; Rees WA; Fujihara K; Paul F; Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Cutter G; She D; Gunsior M; Cimbora D; Katz E; Cree BA;
    J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):757-768. PubMed ID: 37221052
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
    Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M
    Eur J Neurol; 2023 May; 30(5):1389-1399. PubMed ID: 36779855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.
    Koch MW; Cutter GR; Giovannoni G; Uitdehaag BMJ; Wolinsky JS; Davis MD; Steinerman JR; Knappertz V
    Neurol Neuroimmunol Neuroinflamm; 2017 Jul; 4(4):e358. PubMed ID: 28680915
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis.
    Verde F; Milone I; Maranzano A; Colombo E; Torre S; Solca F; Doretti A; Gentile F; Manini A; Bonetti R; Peverelli S; Messina S; Maderna L; Morelli C; Poletti B; Ratti A; Silani V; Ticozzi N
    Ann Clin Transl Neurol; 2023 Jan; 10(1):118-129. PubMed ID: 36525477
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis.
    Sun M; Liu N; Xie Q; Li X; Sun J; Wang H; Wang M
    Mult Scler Relat Disord; 2021 Jun; 51():102870. PubMed ID: 33819724
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinically relevant increases in serum neurofilament light chain and glial fibrillary acidic protein in patients with Susac syndrome.
    Plantone D; Sabatelli E; Locci S; Marrodan M; Laakso SM; Mateen FJ; Feresiadou A; Buelens T; Bianco A; Fiol MP; Correale J; Tienari P; Calabresi P; De Stefano N; Iorio R
    Eur J Neurol; 2023 Oct; 30(10):3256-3264. PubMed ID: 37335505
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
    Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
    Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
    Solanky BS; John NA; DeAngelis F; Stutters J; Prados F; Schneider T; Parker RA; Weir CJ; Monteverdi A; Plantone D; Doshi A; MacManus D; Marshall I; Barkhof F; Gandini Wheeler-Kingshott CAM; Chataway J;
    AJNR Am J Neuroradiol; 2020 Dec; 41(12):2209-2218. PubMed ID: 33154071
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study.
    Højsgaard Chow H; Talbot J; Lundell H; Marstrand L; Gøbel Madsen C; Bach Søndergaard H; Bredahl Hansen M; Solberg Sørensen P; Siebner HR; Sellebjerg F
    Mult Scler Relat Disord; 2023 Feb; 70():104458. PubMed ID: 36586351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Brain-derived neurotrophic factor, neurofilament light and glial fibrillary acidic protein do not change in response to aerobic training in people with MS-related fatigue - a secondary analysis of a randomized controlled trial.
    Gravesteijn AS; Beckerman H; Willemse EA; Hulst HE; de Jong BA; Teunissen CE; de Groot V
    Mult Scler Relat Disord; 2023 Feb; 70():104489. PubMed ID: 36621163
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS/MS and Simoa.
    Wang J; Wang J; Xie W; Liu J; Feng J; Wei W; Li M; Wu L; Wang C; Li R
    Int Immunopharmacol; 2023 Mar; 116():109761. PubMed ID: 36709595
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort.
    Steffen F; Uphaus T; Ripfel N; Fleischer V; Schraad M; Gonzalez-Escamilla G; Engel S; Groppa S; Zipp F; Bittner S
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411080
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study.
    Abdelhak A; Huss A; Stahmann A; Senel M; Krumbholz M; Kowarik MC; Havla J; Kümpfel T; Kleiter I; Wüstinger I; Zettl UK; Schwartz M; Roesler R; Friede T; Ludolph AC; Ziemann U; Tumani H
    Contemp Clin Trials Commun; 2020 Jun; 18():100574. PubMed ID: 32478196
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis.
    Fujimori J; Nakashima I
    J Neurol Sci; 2021 Aug; 427():117528. PubMed ID: 34098375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.